Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report)'s share price was up 14.4% during trading on Thursday . The stock traded as high as $15.99 and last traded at $15.70. Approximately 92,795 shares changed hands during trading, a decline of 14% from the average daily volume of 107,916 shares. The stock had previously closed at $13.72.
Lexeo Therapeutics Stock Performance
The firm has a 50 day moving average price of $13.83. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.15). As a group, research analysts predict that Lexeo Therapeutics, Inc. will post -3.04 earnings per share for the current year.
Institutional Investors Weigh In On Lexeo Therapeutics
A number of institutional investors have recently modified their holdings of LXEO. BNP Paribas Financial Markets purchased a new position in Lexeo Therapeutics in the first quarter valued at $75,000. Cornell University acquired a new stake in Lexeo Therapeutics in the 1st quarter valued at about $1,980,000. Blackstone Inc. purchased a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $9,342,000. Omega Fund Management LLC purchased a new stake in shares of Lexeo Therapeutics during the fourth quarter worth approximately $28,955,000. Finally, Eventide Asset Management LLC purchased a new stake in shares of Lexeo Therapeutics during the fourth quarter worth approximately $40,298,000. 60.67% of the stock is owned by institutional investors and hedge funds.
Lexeo Therapeutics Company Profile
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
